Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: Cancer Res. 2010 Jan 19;70(3):1072. doi: 10.1158/0008-5472.CAN-09-1301

Figure 5.

Figure 5

CD4+ T cells are required for generation of antitumor responses following vaccination with DCAd.Neu, but not DCAd.Neu+Ad.mIL-15+Ad.mIL-15Rα CD4+, CD8+ and NK cell were depleted from groups of BALB/c mice vaccinated with A; DCAd.Neu or B; DCAd.Neu+Ad.mIL-15+Ad.mIL-15Rα, using injections of 200 μg of anti-CD4 (GK1.5) or anti-CD8 (2.43), or 50 μg anti-NK (anti-asialo GM1) antibodies as described in Materials and Methods. Two weeks after the final vaccination mice were injected with 1 × 106 TUBO cells and followed for tumor free survival (10 mice per group).